Free Trial

Nuvation Bio (NUVB) Competitors

Nuvation Bio logo
$2.67 -0.01 (-0.37%)
(As of 12/23/2024 05:26 PM ET)

NUVB vs. VRNA, RYTM, MLTX, EWTX, JANX, XENE, MRUS, ACAD, TWST, and VCEL

Should you be buying Nuvation Bio stock or one of its competitors? The main competitors of Nuvation Bio include Verona Pharma (VRNA), Rhythm Pharmaceuticals (RYTM), MoonLake Immunotherapeutics (MLTX), Edgewise Therapeutics (EWTX), Janux Therapeutics (JANX), Xenon Pharmaceuticals (XENE), Merus (MRUS), ACADIA Pharmaceuticals (ACAD), Twist Bioscience (TWST), and Vericel (VCEL). These companies are all part of the "pharmaceutical products" industry.

Nuvation Bio vs.

Verona Pharma (NASDAQ:VRNA) and Nuvation Bio (NYSE:NUVB) are both medical companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, risk, media sentiment, valuation, community ranking, profitability, analyst recommendations, earnings and dividends.

85.9% of Verona Pharma shares are held by institutional investors. Comparatively, 61.7% of Nuvation Bio shares are held by institutional investors. 4.8% of Verona Pharma shares are held by company insiders. Comparatively, 5.1% of Nuvation Bio shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Verona Pharma currently has a consensus target price of $43.83, indicating a potential downside of 3.19%. Nuvation Bio has a consensus target price of $6.60, indicating a potential upside of 147.19%. Given Nuvation Bio's higher probable upside, analysts clearly believe Nuvation Bio is more favorable than Verona Pharma.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Verona Pharma
0 Sell rating(s)
0 Hold rating(s)
6 Buy rating(s)
0 Strong Buy rating(s)
3.00
Nuvation Bio
0 Sell rating(s)
0 Hold rating(s)
5 Buy rating(s)
0 Strong Buy rating(s)
3.00

Verona Pharma has higher revenue and earnings than Nuvation Bio. Verona Pharma is trading at a lower price-to-earnings ratio than Nuvation Bio, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Verona Pharma$5.62M647.64-$54.37M-$1.92-23.58
Nuvation Bio$2.16M415.65-$75.80M-$2.17-1.23

Verona Pharma has a beta of 0.46, meaning that its share price is 54% less volatile than the S&P 500. Comparatively, Nuvation Bio has a beta of 1.46, meaning that its share price is 46% more volatile than the S&P 500.

Verona Pharma received 279 more outperform votes than Nuvation Bio when rated by MarketBeat users. Likewise, 80.55% of users gave Verona Pharma an outperform vote while only 78.57% of users gave Nuvation Bio an outperform vote.

CompanyUnderperformOutperform
Verona PharmaOutperform Votes
323
80.55%
Underperform Votes
78
19.45%
Nuvation BioOutperform Votes
44
78.57%
Underperform Votes
12
21.43%

Nuvation Bio's return on equity of -21.89% beat Verona Pharma's return on equity.

Company Net Margins Return on Equity Return on Assets
Verona PharmaN/A -79.54% -43.49%
Nuvation Bio N/A -21.89%-17.86%

In the previous week, Nuvation Bio had 3 more articles in the media than Verona Pharma. MarketBeat recorded 8 mentions for Nuvation Bio and 5 mentions for Verona Pharma. Verona Pharma's average media sentiment score of 0.50 beat Nuvation Bio's score of 0.44 indicating that Verona Pharma is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Verona Pharma
1 Very Positive mention(s)
1 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Nuvation Bio
2 Very Positive mention(s)
2 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

Summary

Verona Pharma beats Nuvation Bio on 9 of the 16 factors compared between the two stocks.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

NUVB vs. The Competition

MetricNuvation BioPharmaceutical IndustryMedical SectorNYSE Exchange
Market Cap$898.63M$6.69B$5.20B$19.22B
Dividend YieldN/A3.00%5.12%3.67%
P/E Ratio-1.2310.5287.1941.09
Price / Sales415.65193.661,163.5517.39
Price / CashN/A57.1643.2321.28
Price / Book0.975.134.805.31
Net Income-$75.80M$151.58M$120.46M$989.88M
7 Day Performance-5.15%-1.40%-0.89%-2.50%
1 Month Performance-4.64%-3.69%14.87%-4.68%
1 Year Performance79.19%9.07%29.57%11.56%

Nuvation Bio Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
NUVB
Nuvation Bio
2.3775 of 5 stars
$2.67
-0.4%
$6.60
+147.2%
+79.2%$898.63M$2.16M-1.2360Analyst Forecast
News Coverage
VRNA
Verona Pharma
0.9464 of 5 stars
$43.32
+4.6%
$43.83
+1.2%
+157.9%$3.52B$460,000.00-21.5730
RYTM
Rhythm Pharmaceuticals
4.1031 of 5 stars
$56.23
+1.8%
$63.70
+13.3%
+20.9%$3.46B$77.43M-12.76140Analyst Forecast
News Coverage
Positive News
MLTX
MoonLake Immunotherapeutics
1.6314 of 5 stars
$52.07
+1.4%
$79.88
+53.4%
-13.3%$3.33BN/A-39.802
EWTX
Edgewise Therapeutics
2.4982 of 5 stars
$34.97
+26.6%
$42.33
+21.1%
+221.3%$3.31BN/A-22.8560Gap Up
High Trading Volume
JANX
Janux Therapeutics
3.695 of 5 stars
$62.25
+1.9%
$89.90
+44.4%
+436.9%$3.27B$13.05M-52.2330Positive News
XENE
Xenon Pharmaceuticals
2.8295 of 5 stars
$41.15
+2.7%
$56.90
+38.3%
-14.5%$3.14B$9.43M-14.20251
MRUS
Merus
2.2316 of 5 stars
$42.84
+0.0%
$85.64
+99.9%
+56.8%$2.93B$43.95M-10.8437
ACAD
ACADIA Pharmaceuticals
3.8669 of 5 stars
$17.50
+1.4%
$25.60
+46.3%
-45.3%$2.91B$726.44M22.13510
TWST
Twist Bioscience
2.5927 of 5 stars
$48.94
+3.0%
$51.90
+6.0%
+30.9%$2.91B$312.97M-13.19990
VCEL
Vericel
1.2838 of 5 stars
$58.15
+1.2%
$59.71
+2.7%
+64.1%$2.87B$226.84M957.83300Analyst Upgrade

Related Companies and Tools


This page (NYSE:NUVB) was last updated on 12/24/2024 by MarketBeat.com Staff
From Our Partners